Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 2/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.67 |
| ▸ | NPC1 | O15118 | 1/20 | 0.67 |
| ▸ | CRBN | Q96SW2 | 4/20 | 0.61 |
| ▸ | DDB1 | Q16531 | 2/20 | 0.56 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.53 |
| ▸ | OGA | O60502 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.50 |
| ▸ | HPGDS | O60760 | 1/20 | 0.50 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.48 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL19283913 | 0.99 | KMT2A (0.66) | RAB9AKMT2ANPC1CRBNDDB1 | |
| SCHEMBL5204132 | 0.95 | RAB9A (0.62) | RAB9AKMT2ANPC1CRBNDDB1 | |
| SCHEMBL3895677 | 0.87 | RAB9A (0.72) | RAB9AKMT2ANPC1CRBNDDB1 | |
| Hydrochloric Acid SCHEMBL7357024 | 0.86 | RAB9A (0.58) | RAB9AKMT2ANPC1CRBNDDB1 | |
| SCHEMBL7326778 | 0.85 | RAB9A (0.71) | RAB9AKMT2ANPC1CRBNDDB1 | |
| SCHEMBL20423547 | 0.85 | CRBN (0.57) | RAB9AKMT2ANPC1CRBNDDB1 | |
| SCHEMBL386639 | 0.85 | P2RY12 (0.60) | RAB9AKMT2ANPC1CRBNHRH3 | |
| SCHEMBL1331652 | 0.84 | RAB9A (0.73) | RAB9AKMT2ANPC1CRBNDDB1 | |
| Hydrochloric Acid SCHEMBL25232851 | 0.84 | P2RY12 (0.59) | RAB9AKMT2ANPC1CRBNHRH3 | |
| Hydrochloric Acid SCHEMBL31570844 | 0.84 | P2RY12 (0.59) | RAB9AKMT2ANPC1CRBNHRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12312316-B2 | Compounds and methods for the targeted degradation of androgen receptor | ARVINAS OPERATIONS, INC. (US) | 2025-05-27 | — | — | US | disclosed |
| US-12195472-B2 | Substituted indole Mcl-1 inhibitors | VANDERBILT UNIVERSITY (US) | 2025-01-14 | — | — | US | disclosed |
| WO-2023192989-A2 | PHTHALAZINONE COMPOUNDS AS PARP7 INHIBITORS | AZKARRA THERAPEUTICS, INC. (US) | 2023-10-05 | — | — | WO | disclosed |
| WO-2023192989-A2 | PHTHALAZINONE COMPOUNDS AS PARP7 INHIBITORS | AZKARRA THERAPEUTICS, INC. (US) | 2023-10-05 | — | — | WO | disclosed |
| US-20230039309-A1 | SUBSTITUTED INDOLE MCL-1 INHIBITORS | VANDERBILT UNIVERSITY | 2023-02-09 | — | — | US | disclosed |
| US-11427548-B2 | Compounds and methods for the targeted degradation of androgen receptor | ARVINAS OPERATIONS, INC. (US) | 2022-08-30 | — | — | US | disclosed |
| US-20220144838-A1 | Compounds as Inhibitors of Macrophage Migration Inhibitory Factor | Nanjing Immunophage Biotech Co., Ltd. (CN) | 2022-05-12 | — | — | US | disclosed |
| EP-3419971-B1 | GLYCOSIDASE INHIBITORS | ASCENEURON SA (CH) | 2022-04-20 | — | — | EP | disclosed |
| US-11208415-B2 | Substituted indole Mcl-1 inhibitors | VANDERBILT UNIVERSITY (US) | 2021-12-28 | — | — | US | disclosed |
| US-20210186958-A1 | GLYCOSIDASE INHIBITORS | ASCENEURON SA (CH) | 2021-06-24 | — | — | US | disclosed |
| EP-0934312-A1 | 1,4-DISUBSTITUTED PIPERAZINES | NOVO NORDISK A/S (DK) | 1999-08-11 | — | — | EP | disclosed |
| US-5916889-A | ANTIDIABETIC AGENT; DIETETICS | NOVO NORDISK A/S (DK) | 1999-06-29 | — | — | US | disclosed |
| WO-1999020606-A2 | PIPERIDINES AND PIPERAZINES AS PLATELET AGGREGATION INHIBITORS | J. URIACH & CIA. S.A. (ES) | 1999-04-29 | — | — | WO | disclosed |
| WO-1998015548-A1 | 1,4-DISUBSTITUTED PIPERAZINES | NOVO NORDISK A/S (DK) | 1998-04-16 | — | — | WO | disclosed |
| EP-0385351-B1 | Nicotinic acid derivatives and pharmaceutical compositions comprising same | NISSHIN FLOUR MILLING CO (JP) | 1995-01-11 | — | — | EP | disclosed |
| EP-0385350-B1 | Pyridinecarboxylic acid amide derivatives and pharmaceutical compositions comprising same | NISSHIN FLOUR MILLING CO (JP) | 1994-11-30 | — | — | EP | disclosed |
| US-5025012-A | Cardiovascular disorders; antiischemic agents | NISSHIN FLOUR MILLING CO., LTD. (JP) | 1991-06-18 | — | — | US | disclosed |
| US-4994456-A | Hypotensive agents | NISSHIN FLOUR MILLING CO., LTD. (JP) | 1991-02-19 | — | — | US | disclosed |
| EP-0385351-A1 | Nicotinic acid derivatives and pharmaceutical compositions comprising same | NISSHIN FLOUR MILLING CO., LTD. (JP) | 1990-09-05 | — | — | EP | disclosed |
| EP-0385350-A1 | Pyridinecarboxylic acid amide derivatives and pharmaceutical compositions comprising same | NISSHIN FLOUR MILLING CO., LTD. (JP) | 1990-09-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220144838-A1 | Compounds as Inhibitors of Macrophage Migration Inhibitory Factor | MIF, MMP12, SLC11A2 | RAB9A 1346/4885KMT2A 3645/4885NPC1 160/4885 |
| US-20210186958-A1 | GLYCOSIDASE INHIBITORS | ENGASE, GAA, GLA | RAB9A 931/4885KMT2A 918/4885NPC1 449/4885 |
| US-12312316-B2 | Compounds and methods for the targeted degradation of androgen receptor | AR, MDM2, ESRRA | RAB9A 4010/4885KMT2A 1478/4885NPC1 1813/4885 |
| US-20230039309-A1 | SUBSTITUTED INDOLE MCL-1 INHIBITORS | MCL1, BCL2L1, BCL3 | RAB9A 3796/4885KMT2A 670/4885NPC1 2000/4885 |
| US-12195472-B2 | Substituted indole Mcl-1 inhibitors | MCL1, BCL2L1, BCL3 | RAB9A 3796/4885KMT2A 670/4885NPC1 2000/4885 |
| US-11427548-B2 | Compounds and methods for the targeted degradation of androgen receptor | AR, MDM2, ESRRA | RAB9A 4010/4885KMT2A 1478/4885NPC1 1813/4885 |
| US-11208415-B2 | Substituted indole Mcl-1 inhibitors | MCL1, BCL2L1, BCL3 | RAB9A 3796/4885KMT2A 670/4885NPC1 2000/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.